Bellevue Group AG Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001674546
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q1 2025 · 148 positions · Total reported value $4.46B · Top-10 concentration 48.6% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 61.0% · 17 new · 64 cut · 24 exited
Active Share (vs S&P 500): 94.1% · vs QQQ: 96.5% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q1 2026 → Q2 2026): +12.4% · vs SPY -2.4% · Prev Value $4.20B — last quarter positions weighted by this quarter price moves · ranking
In its Q1 2025 13F filing, Bellevue Group AG disclosed 148 equity positions with a combined reported value of $4.46B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 48.6% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q1 2025 were ARGX ($342.62M), IONS ($236.93M), SYK ($210.92M). By sector, the heaviest allocations are Health Care 94.1%, Industrials 1.8%. Versus the prior quarter, allocation shifted toward Health Care (+4.2pp) and away from Other (-4.0pp).
Versus the prior quarter, Bellevue Group AG opened 17 new positions, trimmed 64 and fully exited 24, a turnover rate of 61.0% of positions. The portfolio's overlap with the prior quarter was 81% of names.
The largest new positions opened in Q1 2025 were AKRO ($50.63M), BAX ($15.62M), KMTS ($3.33M).
Of the 24 positions fully exited versus the prior quarter, the largest were ITCI ($203.81M), ARVN ($45.81M), TNDM ($28.18M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q1 2025)
- AKRO AKERO THERAPEUTICS INC · $50.63M
- BAX BAXTER INTL INC · $15.62M
- KMTS KESTRA MEDICAL TECHNOLOGIES · $3.33M
- SNY SANOFI SA · $887.36K
- BBNX BETA BIONICS INC · $817.94K
- IWM ISHARES TR · $458.83K
- EXEL EXELIXIS INC · $313.82K
- AMZN AMAZON COM INC · $171.23K
Fully Exited (vs previous quarter)
- ITCI INTRA-CELLULAR THERAPIES INC · prev qtr: $203.81M
- ARVN ARVINAS INC · prev qtr: $45.81M
- TNDM TANDEM DIABETES · prev qtr: $28.18M
- SAGE SAGE THERAPEUTICS INC · prev qtr: $24.22M
- CRL CHARLES RIV LABS INTL INC · prev qtr: $9.29M
- FATE Fate Therapeutics Inc · prev qtr: $7.99M
- TERN TERNS PHARMACEUTICALS INC · prev qtr: $5.88M
- OMCL OMNICELL COM · prev qtr: $4.22M
Insider Transactions (Form 4)
Latest Bellevue Group AG buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.
Fund Profile
Bellevue Group AG files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q2 2026) lists 148 positions worth $4.75B in total. HoldingsHub carries 12 quarters of its filings (Q3 2023–Q2 2026).
Portfolio Structure
- 148 positions · $4.75B reported value (Q2 2026)
- Top 10 holdings = 42.9% of reported value
- Largest position: AMGN (AMGEN INC) at 6.5%
- Average position size: $32.11M
Sector Tilt
- Health Care 92.6%
- Industrials 1.7%
- Information Technology 0.4%
- (classified holdings cover 95% of value)
Quarterly Activity
- Q2 2026: 17 new, 39 added, 64 reduced, 24 exited
- 28 positions unchanged
Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.
Sector Allocation
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
578.87K | $342.62M | 7.68% | Reduce | |
| 2 |
|
7.85M | $236.93M | 5.31% | Hold | |
| 3 |
|
566.60K | $210.92M | 4.73% | Add | |
| 4 |
|
425.75K | $210.86M | 4.72% | Reduce | |
| 5 |
|
768.15K | $207.42M | 4.65% | Hold | |
| 6 |
|
1.56M | $206.42M | 4.62% | Reduce | |
| 7 |
|
1.82M | $201.29M | 4.51% | Hold | |
| 8 |
|
413.07K | $200.27M | 4.49% | Reduce | |
| 9 |
|
1.95M | $196.82M | 4.41% | Reduce | |
| 10 |
|
4.37M | $154.68M | 3.47% | Hold | |
| 11 |
|
2.09M | $126.66M | 2.84% | Reduce | |
| 12 |
|
3.52M | $102.99M | 2.31% | Hold | |
| 13 |
|
164.74K | $86.28M | 1.93% | Add | |
| 14 |
|
938.36K | $84.32M | 1.89% | Reduce | |
| 15 |
|
2.51M | $80.60M | 1.81% | Hold | |
| 16 |
|
344.31K | $78.87M | 1.77% | Add | |
| 17 |
|
1.06M | $72.67M | 1.63% | Add | |
| 18 |
|
271.29K | $71.24M | 1.60% | Reduce | |
| 19 |
|
971.97K | $70.45M | 1.58% | Reduce | |
| 20 |
|
3.07M | $55.75M | 1.25% | Hold | |
| 21 |
|
204.52K | $54.69M | 1.23% | Reduce | |
| 22 |
|
1.25M | $50.63M | 1.13% | New | |
| 23 |
|
2.04M | $49.06M | 1.10% | Hold | |
| 24 |
|
2.40M | $46.79M | 1.05% | Add | |
| 25 |
|
1.52M | $43.04M | 0.96% | Add | |
| 26 |
|
524.41K | $42.33M | 0.95% | Hold | |
| 27 |
|
117.53K | $38.67M | 0.87% | Reduce | |
| 28 |
|
165.80K | $37.11M | 0.83% | Add | |
| 29 |
|
1.22M | $36.25M | 0.81% | Add | |
| 30 |
|
43.65K | $36.05M | 0.81% | Reduce | |
| 31 |
|
4.09M | $33.08M | 0.74% | Hold | |
| 32 |
|
291.35K | $32.97M | 0.74% | Reduce | |
| 33 |
|
76.90K | $32.29M | 0.72% | Hold | |
| 34 |
|
64.23K | $31.96M | 0.72% | Add | |
| 35 |
|
1.43M | $31.44M | 0.70% | Hold | |
| 36 |
|
357.02K | $30.12M | 0.68% | Hold | |
| 37 |
|
135.24K | $28.34M | 0.64% | Add | |
| 38 |
|
113.25K | $26.23M | 0.59% | Reduce | |
| 39 |
|
368.37K | $26.04M | 0.58% | Add | |
| 40 |
|
124.32K | $25.49M | 0.57% | Add | |
| 41 |
|
80.94K | $25.22M | 0.56% | Reduce | |
| 42 |
|
579.07K | $25.07M | 0.56% | Reduce | |
| 43 |
|
75.89K | $25.00M | 0.56% | Reduce | |
| 44 |
|
109.89K | $24.91M | 0.56% | Hold | |
| 45 |
|
332.34K | $24.33M | 0.55% | Reduce | |
| 46 |
|
414.92K | $24.17M | 0.54% | Reduce | |
| 47 |
|
150.99K | $23.99M | 0.54% | Reduce | |
| 48 |
|
61.81K | $21.36M | 0.48% | Hold | |
| 49 |
|
231.37K | $20.77M | 0.47% | Reduce | |
| 50 |
|
30.58K | $20.58M | 0.46% | Add | |
FAQ
What did Bellevue Group AG buy in 2025-Q1?
In its 2025-Q1 13F filing, Bellevue Group AG reported 148 equity positions worth $4.46B in aggregate; its largest disclosed positions were ARGX ($342.62M), IONS ($236.93M), SYK ($210.92M).
How large is Bellevue Group AG's portfolio?
Bellevue Group AG reported $4.46B of long equity holdings across 148 positions as of 2025-Q1. Top-10 holdings account for 48.6% of reported value.
What is Bellevue Group AG's investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.